Analyzing glomerular renin angiotensin system with peptidomics for development of therapeutic and diagnostic methods inhibiting disease progression of chronic kidney disease
Project/Area Number |
26461614
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pediatrics
|
Research Institution | The University of Tokushima |
Principal Investigator |
KAGAMI Shoji 徳島大学, 大学院医歯薬学研究部(医学系), 教授 (00224337)
|
Co-Investigator(Kenkyū-buntansha) |
漆原 真樹 徳島大学, 病院, 講師 (50403689)
谷口 寿章 徳島大学, 先端酵素学研究所(次世代), 教授 (10257636)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 慢性腎臓病 / レニンアンジオテンシン系 / アンジオテンシンII / ぺプチドミクス解析 / 糸球体内皮細胞 / ACE2 / ペプチドミクス解析 / Carboxypeptidase A / 尿バイオマーカー / レニン・アンジオテンシン系 / アンジオテンシノーゲン / 培養細胞 |
Outline of Final Research Achievements |
In order to explore the therapeutic and diagnostic methods inhibiting disease progression in pediatric patients with chronic kidney disease(CKD), this study focused on analyzing the glomerular renin angiotensin system related peptides with peptidomics. We found the ACE2-dependent Ang II degradation system in glomerular mesangial cells and podocytes strongly worked in patients with CKD. Additionally, level of urinary ACE2 excretion parallels with the levels of glomerular cell proliferation as well as urinary protein excretion. Therefore, we propose that control of ACE2 expression within glomeruli may offers a new therapeutic method and measurement of urinary ACE2 may be an indicator for evaluating the severity of pediatric patients with CKD.
|
Report
(4 results)
Research Products
(28 results)
-
-
[Journal Article] Evidence-based clinical practice guidelines for IgA nephropathy 2014.2016
Author(s)
Yuzawa Y, Yamamoto R, Takahashi K, Katafuchi R, Tomita M, Fujigaki Y, Kitamura H, Goto M, Yasuda T, Sato M, Urushihara M, Kondo S, Kagami S, Yasuda Y, Komatsu H, Takahara M, Harabuchi Y, Kimura K, Matsuo S.
-
Journal Title
Clin Exp Nephrol
Volume: 20
Pages: 511-535
Related Report
Peer Reviewed
-
[Journal Article] Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan.2016
Author(s)
Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S.
-
Journal Title
Clin Exp Nephrol
Volume: 20
Pages: 549-555
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Nitrosonifedipine ameliorates the progression of type 2 diabetic nephropathy by exerting antioxidative effects.2014
Author(s)
Ishizawa K, Izawa-Ishizawa Y, Yamano N, Urushihara M, Sakurada T, Imanishi M, Fujii S, Nuno A, Miyamoto L, Kihira Y, Ikeda Y, Kagami S, Kobori H, Tsuchiya K, Tamaki T.
-
Journal Title
PLoS One.
Volume: 9(1)
Issue: 1
Pages: 86335-86335
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-